Suzuki et al. found that Her2 overexpression has a statistically significant association with Her2 mutation in NSCLC; however, immunohistochemistry showed low sensitivity and specificity for identifying the Her2 mutation. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.